Released on January 11, 2012

Recently, GLS 4, a new drug jointly developed by the Center and Dongguan Chang’an HEC New Drug Research & Development Co., Ltd, has obtained the approval document for the Phase I clinical test issued by State Food and Drug Administration (SFDA). 

GLS4 is a brand-new anti-viral compound with the independent intellectual property right structure protection, which has applied for the patent in China, and has also applied for PCT. 

The pre-clinical studies (including a series of experimental studies such as pharmaceutical test, in vivo and in vitro pharmacodynamic tests, acute toxicity tests and pharmacokinetic tests) to evaluate the Project from different aspects have indicated that GLS4 has a significant anti-HBV effect, with good development prospect. Obtaining the approval document for the Phase I clinical test this time is a sign that the R& D of the drug has made an important staged progress. 

In China, the annual direct economic loss caused by chronic HBV and its related diseases is nearly 200 billion yuan. This kind of disease has become a heavy mental burden for many patients. If the drug is successfully developed, it will become a first-line drug for the clinical treatment of HBV, and will also increase the R&D level of anti-HBV drugs to a new one.